Santhera Pharmaceuticals (SPHDF) Stock Price, News & Analysis

Company Overview

Santhera Pharmaceuticals is a Switzerland-based specialty pharmaceutical company focused on developing and commercializing treatments for rare neuromuscular diseases. The company’s work is directed toward conditions with significant unmet medical needs, including Duchenne muscular dystrophy and other inherited muscle disorders.

Santhera’s lead product is vamorolone, marketed in the United States as Agamree. Vamorolone is a corticosteroid designed for the treatment of Duchenne muscular dystrophy and has received regulatory approval in the United States and Europe. Santhera commercializes the product directly in certain markets and works with regional partners in other territories.

The company has also developed treatments and investigational therapies for additional rare diseases. Its former product idebenone, marketed as Raxone for Leber’s hereditary optic neuropathy in Europe, was an earlier part of Santhera’s commercial portfolio. Santhera is headquartered in Pratteln, Switzerland, and serves patients through a combination of direct commercial operations and partnerships across international markets.

Key Stats

• Today's Range: $18.30 to $18.30
• 50-Day Range: $18.30 to $23.25
• 52-Week Range: $18.30 to $19.79
• Volume: N/A
• Average Volume: 1,521 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:SPHDF
• CIK: N/A
• Web: www.santhera.com
• Phone: (161) 906-8950
• Fax: N/A
• Employees: 45
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A